EU Resorcinol Classification 2026: RAC Recommends Endocrine Disruptor Classification For Human Health

The regulatory status of resorcinol (CAS No. 108-46-3; EC No. 203-585-2) is entering a significant new phase in the European Union.

In June 2026, the European Chemicals Agency’s (ECHA) Committee for Risk Assessment (RAC) adopted an opinion recommending, for the first time, a harmonized classification of resorcinol as an endocrine disrupting substance for human health. ECHA confirmed the development as part of its June 2026 RAC meeting highlights.

The recommendation is particularly relevant because resorcinol is used across a broad range of industrial and consumer applications, including rubber products, wood-related products, dyes, chemicals, hair colors and cosmetics.

However, businesses should distinguish between a RAC opinion and a legally binding harmonized classification. The opinion has been sent to the European Commission, which must decide whether to incorporate the classification into Annex VI of the EU CLP Regulation through the applicable legislative process.

What Is the 2026 Resorcinol Regulatory Development?

Resorcinol is already subject to harmonized hazard classifications under the EU chemicals framework. A new CLH proposal submitted by France opened the question of endocrine disruption for human health.

The ECHA registry records the proposed additional classification as:

• Endocrine Disruptor for Human Health – Category 1 (ED HH 1)
• EUH380 – May cause endocrine disruption in humans

The CLH proposal also maintained or addressed other existing hazard classifications, including acute toxicity, skin irritation, eye irritation, skin sensitization, specific target organ toxicity and aquatic hazard classifications.

The RAC opinion was adopted on 5 June 2026. The ECHA registry identifies the proposal as an adopted opinion that is now in the decision-making stage.

Important: RAC Opinion ≠ Final Classification

The RAC is responsible for scientific risk assessment and prepares opinions on CLH proposals. The European Commission makes the final decision on harmonized classification and labelling.

If the Commission adopts the classification, it can subsequently become part of Part 3 of Annex VI to the CLP Regulation, after completion of the relevant legislative process. Once included, the harmonized classification becomes legally binding for the applicable hazard classes.

Why Is Resorcinol Important for Industry?

Resorcinol is a versatile chemical intermediate and functional ingredient used in multiple sectors.

Its applications include:

ECHA's RAC documentation describes resorcinol as being used in industrial and consumer products including rubber products, wood adhesives, dyes, hair colors and other applications.

Because of this broad use profile, a new harmonized hazard classification could have implications beyond chemical manufacturers. Formulators, importers, downstream users, distributors and consumer-product manufacturers may also need to review their regulatory position.

Endocrine Disruption: What Does the Proposed Classification Mean?

Endocrine disruptors are substances that can interfere with the endocrine system and potentially produce adverse effects in humans or the environment.

Under the EU CLP framework, endocrine disruption for human health is recognized as one of the hazard classes for which harmonized classification can be established. ECHA identifies endocrine disruption, alongside CMR hazards, PBT/vPvB and PMT/vPvM properties, among hazards of high regulatory concern.

The resorcinol proposal is therefore significant because it moves the substance into an increasingly important area of EU chemical hazard regulation.

The scientific assessment has considered evidence from different sources, including toxicological and human information. ECHA's earlier regulatory work on resorcinol had already identified endocrine disruption as an area requiring assessment.

The RAC documentation also discusses toxicokinetic information, including absorption and metabolism of resorcinol.

Scientific and Regulatory Background

Resources have been under regulatory attention for several years.

Earlier substance evaluation work examined its potential endocrine-disrupting properties, while regulatory risk-management activities subsequently considered whether additional harmonized classification could improve risk management.

The current CLH process followed the established EU procedure:

1. CLH intention
2. Submission of a CLH dossier
3. ECHA accordance check
4. Public consultation
5. Review of comments and supporting evidence
6. RAC scientific assessment
7. Adoption of the RAC opinion
8. European Commission decision
9. Potential inclusion in CLP Annex VI

ECHA explains that the normal CLH consultation allows interested parties to provide information and comments, after which RAC evaluates the dossier, consultation responses and other relevant evidence.

For resorcinol, the consultation began in January 2025, with a deadline for commenting in March 2025. The registry records the RAC opinion date as 5 June 2026.

What Could Change If the Classification Is Adopted?

A final harmonized classification could affect several regulatory activities across the chemical supply chain.

1. Classification and Labelling

Companies placing resorcinol on the EU market would need to assess their classification and labelling obligations against the final Annex VI entry once adopted.

This can affect:

• Hazard statements
• Precautionary statements
• Signal words
• Pictograms
• Packaging information
• Safety Data Sheets
• Product documentation

ECHA states that once a harmonized classification is included in Annex VI, it becomes legally binding for the relevant hazard classes.

2. Mixture Classification

Companies using resorcinol in mixtures should evaluate whether the final classification changes the hazard classification of their formulations.

This is particularly important for:

• Chemical mixtures
• Hair color products
• Cosmetic formulations
• Industrial formulations
• Cleaning products
• Adhesive systems
• Specialty chemical products

The impact will depend on the final classification, concentration and applicable CLP rules.

3. Safety Data Sheets

Safety Data Sheets should be reviewed when new hazard information becomes legally applicable.

Companies may need to reassess:

• Section 2 – Hazard identification
• Section 3 – Composition/information on ingredients
• Section 8 – Exposure controls
• Section 11 – Toxicological information
• Section 12 – Ecological information
• Section 15 – Regulatory information

4. Product Portfolio Review

Companies using resorcinol across multiple formulations should establish where the substance is present and determine which products may be affected.

A portfolio review should cover:

Raw materials → intermediates → formulations → finished products → labels → SDS → technical documentation → market-specific compliance

What Should Companies Do Now?

Although the final EU decision has not yet been adopted, companies can begin preparing.

Resorcinol and Cosmetics: Why Cosmetic Companies Should Pay Attention

Resorcinol is particularly relevant to the hair color and cosmetics sector.

A potential EU CLP classification does not automatically mean that every cosmetic product containing resorcinol becomes prohibited. Cosmetic compliance operates under its own regulatory framework, and the effect of a CLP classification must be assessed together with the applicable cosmetic legislation and product-specific requirements.

However, companies should not treat CLP development in isolation.

A robust review should be considered:

• Ingredient identity and concentration
• Intended cosmetic use
• Product category
• Safety assessment
• Ingredient restrictions
• Labelling requirements
• Consumer exposure
• Professional-use exposure
• Supplier specifications
• SDS and raw material documentation
• Future regulatory restrictions or risk-management measures

This is especially important for manufacturers and brand owners operating across multiple EU markets.

Key Business Implications

The potential harmonized classification could create a broader compliance impact across the supply chain.

1. Manufacturers

Manufacturers should assess whether resorcinol is manufactured, processed or incorporated into mixtures and determine whether future classification changes could affect hazard communication and product stewardship.

2. Importers

Importers should verify supplier documentation and prepare for potential changes to SDS, labels and classification information.

3. Downstream Users

Downstream users should evaluate whether their intended uses and mixtures remain appropriately classified and documented.

4.Distributors

Distributors should monitor updated supplier documentation and ensure products are supplied with compliant labels and packaging when new requirements become applicable.

5. Consumer-Product Companies

Companies selling products containing resorcinol should assess whether changes to chemical classification could trigger additional product-level reviews.

Regulatory Readiness Checklist

Before the European Commission makes its decision, companies should consider the following:

• Identify all resorcinol-containing products
• Verify CAS No. 108-46-3 and EC No. 203-585-2
• Review current CLP classification
• Map resorcinol concentrations across formulations
• Review SDS and technical documentation
• Evaluate potential mixture-classification implication
• Review cosmetic and hair-color applications separately
• Assess supplier and downstream-user communication
• Monitor European Commission decision-making
• Track the relevant CLP Adaptation to Technical Progress
• Prepare label and SDS update workflows
• Maintain regulatory evidence and change-control records

FAQs

1. Is resorcinol already classified under EU CLP?

Yes. Resorcinol already has harmonized classifications under the EU chemicals framework. The 2026 CLH process concerns an additional proposed classification relating to endocrine disruption for human health.

2. Has resorcinol already been legally classified as an endocrine disruptor?

Not yet through this process. RAC adopted its scientific opinion in June 2026, but the European Commission still must decide whether to adopt the harmonized classification.

3. What classification did RAC recommend?

The CLH proposal and ECHA registry identify the proposed endocrine-disruption classification as ED HH 1 – Endocrine Disruptor for Human Health, Category 1, with EUH380.

4. Will the change affect cosmetics?

Potentially. Companies using resorcinol in cosmetics and hair-color products should monitor the CLP process and assess the interaction with applicable cosmetic product requirements.

5. Should companies wait for the final Commission decision?

Companies can begin regulatory impact assessment and portfolio mapping now. Waiting until a final legislative act is published may leave limited time for SDS, labelling and formulation reviews.

Conclusion

The June 2026 RAC opinion on resorcinol represents an important development in EU chemical hazard classification.

For the first time in this CLH process, RAC has recommended classification of resorcinol as an endocrine disrupting substance for human health. The opinion has now moved to the European Commission for decision-making.

For manufacturers, importers, formulators, downstream users and consumer-product companies, the key priority is regulatory readiness.

Businesses should identify where resorcinol is used, review concentrations and existing classifications, evaluate potential SDS and labelling impacts, and monitor the Commission's next steps.

Early preparation can help companies manage regulatory change systematically rather than responding after a new harmonized classification becomes legally applicable.

How Maven Regulatory Solutions Can Help

Maven Regulatory Solutions supports companies with regulatory strategy, chemical compliance, classification and labelling, SDS review, formulation assessment and market-access planning.

Our support can include:

• EU CLP Classification & Labelling Review
• Chemical Regulatory Compliance
• REACH Regulatory Support
• SDS & Hazard Communication Review
• Formulation & Ingredient Assessment
• Chemical Portfolio Screening
• Regulatory Impact Assessment
• Product Labelling Compliance
• Regulatory Intelligence & Monitoring
• Market Entry & Lifecycle Compliance

Stay ahead of chemical regulatory change with science-led, market-focused regulatory support.